StockVS

FONAR Corporation (FONR) Stock Analysis

Healthcare

FONAR Corporation

$18.91

+$0.02 (+0.08%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

FONAR Corporation is a specialized entity within the healthcare sector, specifically focusing on diagnostics and research, where it designs, manufactures, sells, and services magnetic resonance imaging scanners for detecting and diagnosing human diseases and medical conditions in the United States. Operating as a small-cap medical technology firm, the company serves the critical need for advanced imaging equipment that supports clinical decision-making across various medical specialties. The business operates at a scale defined by a market capitalization of $117.00M and annual revenue of $106.03M, supported by an employee base of 535 individuals dedicated to engineering and servicing their MRI systems. These valuation and revenue figures indicate that FONAR functions as a niche player rather than a broad-market dominant force, suggesting its position is heavily reliant on its specific product lines and service contracts within the MRI scanner market.

Financial Health

The company generated revenue of $106.03M over the trailing twelve months, resulting in a net income of $7.19M and an EBITDA of $15.05M. The significant gap between the $106.03M in revenue and the $7.19M in net income reveals a cost structure where operating expenses, taxes, and interest costs absorb approximately 92.9% of gross revenue before reaching the bottom line. The business maintains free cash flow of $2.44M, which indicates a positive ability to generate cash from operations after capital expenditures, providing a baseline for financial flexibility despite high fixed costs associated with manufacturing and servicing heavy medical equipment. Profitability is segmented across three key margins: a gross margin of 40.8%, an operating margin of 11.7%, and a profit margin of 7.1%. The 40.8% gross margin suggests that the cost of goods sold is roughly 59.2% of revenue, while the drop to an 11.7% operating margin highlights substantial overhead expenses, and the final 7.1% profit margin reflects the net impact of all corporate-level costs and taxes. Liquidity management is characterized by a cash balance of $53.10M against total debt of $39.80M, yielding a debt-to-equity ratio of 24.44. This leverage structure indicates a balance sheet that utilizes debt to finance operations, though the absolute debt level is well-covered by cash reserves. Short-term liquidity is exceptionally strong, evidenced by a current ratio of 10.00, which implies the company holds ten times more current assets than current liabilities, ensuring it can easily meet obligations as they come due. Return metrics show a return on equity of 6.0% and a return on assets of 3.2%, revealing that management effectiveness in generating profit from shareholder equity is moderate, while the return on assets is relatively low, suggesting capital intensity or the use of leverage to drive returns.

Valuation Assessment

The stock carries a trailing P/E ratio of 16.15, while the forward P/E is listed as N/A, implying that analysts may not have a consensus projection for next year's earnings or that the market is pricing the stock based on current performance rather than expected future growth acceleration. A price-to-book ratio of 0.69 indicates that the market values the company at less than its net asset value, suggesting a lack of market premium over book value and potentially a perception of undervaluation or specific risks associated with the business model. Alternative valuation metrics further define the investment case, with a price-to-sales ratio of 1.10 and an EV/EBITDA of 6.27. The P/S ratio suggests the market is willing to pay slightly more than one dollar in valuation for every dollar of sales, while the low EV/EBITDA of 6.27 points to a relatively cheap valuation relative to its earnings power before interest, taxes, depreciation, and amortization. Price action over the last year has oscillated between a 52-week high of $18.86 and a 52-week low of $12.00. To determine the current trading position relative to this range, one must calculate the distance from the extremes; however, without the specific current price, the stock's volatility is contextualized by a beta of 1.02. This beta value indicates that the stock's price volatility moves in tandem with the broader market, showing slightly higher sensitivity than the market average but without significant amplification of market swings.

Growth & Income

The company reports a revenue growth rate of 2.4% and an earnings growth rate of 1.1% year-over-year. Earnings are growing slower than revenue, as the 1.1% earnings growth lags behind the 2.4% revenue expansion, which implies that the cost structure or margin compression is outpacing top-line growth, preventing a more efficient conversion of sales into net income. Regarding income generation, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Because the payout ratio is zero, the company reinvests all of its earnings back into the business or retains them on the balance sheet rather than distributing cash to shareholders. The overall growth and income profile characterizes FONAR as a non-dividend stock with modest single-digit growth in both revenue and earnings, relying on capital appreciation rather than yield to provide total shareholder return.

Peer Comparison

FONAR Corporation (FONR) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
FONAR Corporation FONR $119.06M 18.9
Thermo Fisher Scientific Inc. TMO $166.55B 24.6
Danaher Corporation DHR $122.31B 33.4
IDEXX Laboratories, Inc. IDXX $43.95B 41.0

The Diagnostics & Research industry average P/E ratio is 32.5x. FONAR Corporation trades at a P/E of 18.9.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About FONAR Corporation

FONAR Corporation, together with its subsidiaries, engages in the designing, manufacturing, selling, and servicing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries in the United States. It operates in two segments: Medical Equipment, and Physician Management and Diagnostic Services. The company offers an Upright MRI scanner, which allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. It also provides non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with legal and regulatory matters, and development and implementation of practice growth and marketing strategies. In addition, the company owns and operates diagnostic imaging facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1978 and is based in Melville, New York.

Visit website →

Key Statistics

Market Cap
$119.06M
P/E Ratio
18.91
52-Week High
$18.95
52-Week Low
$13.62
Avg Volume
51.78K

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NASDAQ
Country
United States
Employees
535